Virginia Retirement Systems ET AL lowered its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 18.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,200 shares of the biopharmaceutical company’s stock after selling 2,600 shares during the period. Virginia Retirement Systems ET AL’s holdings in Vanda Pharmaceuticals were worth $183,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Vanda Pharmaceuticals by 26.4% in the 1st quarter. Vanguard Group Inc. now owns 2,494,347 shares of the biopharmaceutical company’s stock valued at $34,920,000 after acquiring an additional 521,669 shares during the period. Point72 Asset Management L.P. increased its position in Vanda Pharmaceuticals by 1,544.3% in the 1st quarter. Point72 Asset Management L.P. now owns 2,484,500 shares of the biopharmaceutical company’s stock valued at $34,783,000 after acquiring an additional 2,333,400 shares during the period. FMR LLC increased its position in Vanda Pharmaceuticals by 60.7% in the 1st quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock valued at $22,416,000 after acquiring an additional 604,900 shares during the period. Renaissance Technologies LLC increased its position in Vanda Pharmaceuticals by 65.3% in the 1st quarter. Renaissance Technologies LLC now owns 939,250 shares of the biopharmaceutical company’s stock valued at $13,150,000 after acquiring an additional 370,900 shares during the period. Finally, Prudential Financial Inc. increased its position in Vanda Pharmaceuticals by 0.8% in the 1st quarter. Prudential Financial Inc. now owns 614,318 shares of the biopharmaceutical company’s stock valued at $8,600,000 after acquiring an additional 4,700 shares during the period. Institutional investors and hedge funds own 86.49% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/13/vanda-pharmaceuticals-inc-vnda-shares-sold-by-virginia-retirement-systems-et-al.html.

Several equities analysts recently issued reports on the company. Jefferies Group LLC restated a “buy” rating and issued a $21.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, August 29th. Zacks Investment Research cut Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 18th. Piper Jaffray Companies restated an “overweight” rating and issued a $23.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, June 27th. BidaskClub upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. Finally, HC Wainwright set a $18.00 price target on Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $21.25.

Shares of Vanda Pharmaceuticals Inc. (VNDA) opened at 17.25 on Wednesday. Vanda Pharmaceuticals Inc. has a one year low of $12.70 and a one year high of $18.00. The stock’s market cap is $773.80 million. The firm has a 50-day moving average price of $16.25 and a 200-day moving average price of $15.09.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.18. The firm had revenue of $42.06 million for the quarter, compared to analyst estimates of $40.31 million. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. Vanda Pharmaceuticals’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.01 earnings per share. Analysts anticipate that Vanda Pharmaceuticals Inc. will post ($0.44) earnings per share for the current fiscal year.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Stock Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.